Conditions: Crohn´s Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 20
Healthy volunteers: no

Brief summary:
The purpose of this trial is to demonstrate that Pentasa administered as a 2 g morning dose and a 4 g evening dose is efficacious in active mild to moderate CD.

Detailed description:

Arms:
arm 1: Mesalazine (Mesalamine) 2 g sachet; 6 g daily arm 2: Placebo to Mesalazine (Mesalamine) 2 g sachet; 6 g daily

Interventions: intervention 1: Pentasa intervention 2: Placebo
Intervention descriptions: intervention 1: 6 g/day orally, 2 g in the morning and 4 g in the evening intervention 2: 6 g/day orally, 2 g in the morning and 4 g in the evening

Protocol document: